Biogen BIIB and partner Eisai announced that the European Commission (EC) has granted marketing authorization to Leqembi (lecanemab) for early Alzheimer’s disease (AD). The regulatory body has ...

Biogen Inc. (NASDAQ:BIIB – Free Report) – Analysts at Leerink Partnrs decreased their Q2 2025 earnings per share (EPS) estimates for Biogen in a research report issued on Sunday, April 13th.

Eisai and Biogen can finally put their European regulatory uncertainty surrounding Alzheimer's disease medicine Leqembi behind them and focus on the drug's launch in the region. After months of ...

April 15 (Reuters) - The European Commission on Tuesday authorized the use of Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab drug to treat some patients with mild cognitive ...

Shares of Biogen Inc. BIIB shed 1.44% to $115.29 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 2.24% to 5,275.70 and ...

Eisai and Biogen have received marketing authorisation (MA) from the European Commission (EC) for Leqembi (lecanemab) to treat Alzheimer's disease. This authorisation makes the amyloid-beta (Aβ ...

Also Read: Alzheimer’s Drugs From Eli Lilly And Biogen Still Deemed Too Costly For NHS Funding Protofibrils are a key toxic form of Aβ that accumulate in the brain and cause neuronal injury.

The 2025 Stanley Cup Playoffs got underway Saturday when the Winnipeg Jets defeated the St. Louis Blues 5-3 in Game 1 of the Western Conference First Round. Also on Saturday, the Avalanche ...

Biogen Inc. Tim Power + 1-781-464-2442 [email protected] (mailto:[email protected]) Notes to Editors About lecanemab (generic name, brand name: Leqembi ® ) Lecanemab is the result of a strategic research ...

And it isn’t because he takes joy in crushing the competition. He really wants to show the difference between Cup racing and the Xfinity Series. And he wants to prove to young, up-and-coming ...

The European Commission has approved Eisai and Biogen's Leqembi in Alzheimer's disease. Kyowa Kirin has finished the build-out of a Japanese biologics plant. And more. The Trump administration has ...

Beleaguered Biogen has been handed some encouraging news from the FDA, after the regulator agreed to complete its review of amyotrophic lateral sclerosis (ALS) therapy tofersen within six months.